6533b831fe1ef96bd12999ca

RESEARCH PRODUCT

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Andrea ChiricozziLucia Di NardoMarina TalamontiMarco GalluzzoClara De SimoneGabriella FabbrociniAngelo Valerio MarzanoGiampiero GirolomoniAnnamaria OffidaniMaria Teresa RossiLuca BianchiAntonio CristaudoMaria Teresa FierroLuca StingeniGiovanni PellacaniGiuseppe ArgenzianoAnnalisa PatriziPaolo PigattoMarco RomanelliPaola SavoiaPietro RubegniCaterina FotiNicola MilanesiAnna Belloni FortinaMaria Rita BongiornoTeresa GriecoSergio Di NuzzoMaria Concetta FargnoliAndrea CarugnoAlberico MotoleseFranco RongiolettiPaolo AmerioRiccardo BalestriConcetta PotenzaGiuseppe MicaliCataldo PatrunoIris ZalaudekMaurizio LombardoClaudio FelicianiFlaminia AntonelliSilvia Mariel FerrucciFabrizio GuarneriKetty PerisKatharina Hansel

subject

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti

description

N/A

10.1097/der.0000000000000814https://hdl.handle.net/10447/582525